Oncology

One in three people will develop cancer during
their lifetime, and twenty million people are currently living with cancer in the UK.
 
Oncology clinical drug development takes on average 9.5 years and has a success rate of 5% - 26% moving from Phase I through to FDA/EMA/MHRA approval. Managing development risk is critical as is managing up-front costs leading up to commercialisation. Onorach have expertise in managing risk across oncology Phase I to IV studies.
 
Seamless services delivered throughout clinical development ensures the success of oncology studies. Onorach’s services include: study management, supervision of monitoring, regulatory, quality assurance, medical reporting etc. From early phase to post-marketing, Onorach are practiced in using safety information to make critical decisions; which requires precise coordination. Our approach is one that integrates safety across both time and function.
 
From Phase I to post-marketing, risks are mitigated using:
  • Group Management to oversee study
  • Strategy and Optimisation
  • Safety Risk Profiling
  • Operational Safety
  • Risk Management Analysis
  • Publishing findings

Contact Us for more information...

Client Testimonial

Prof. Leiper and her team at Onorach have demonstrated competencies in many areas in both working with the authorities and with the sites as monitors. They impressed us deeply with highly motivated, goal-oriented staff members of lively personality and creativity. It was always a pleasure to cooperate with Onorach Clinical.
A German Client

 

Join Our MAILING LIST